Table 2 Clinical trials with mRNA vaccines against infectious diseases

From: mRNA vaccines — a new era in vaccinology

Sponsoring institution Vaccine type (route of administration) Targets Trial numbers (phase) Status
Argos Therapeutics DC EP with autologous viral Ag and CD40L mRNAs (i.d.) HIV-1 • NCT00672191 (II)
• NCT01069809 (II)
• NCT02042248 (I)
• Completed105
• Completed; results NA
• Completed; results NA
CureVac AG RNActive viral Ag mRNA (i.m., i.d.) Rabies virus NCT02241135 (I) Active56,91
Erasmus Medical Center DC loaded with viral Ag mRNA with TriMix (i.nod.) HIV-1 NCT02888756 (II) Recruiting
Fundació Clínic per la Recerca Biomèdica Viral Ag mRNA with TriMix (NA) HIV-1 NCT02413645 (I) Active
Massachusetts General Hospital DC loaded with viral Ag mRNA (i.d.) HIV-1 NCT00833781 (II) Completed104
McGill University Health Centre DC EP with autologous viral Ag and CD40L mRNAs (i.d.) HIV-1 NCT00381212 (I/II) Completed102
Moderna Therapeutics Nucleoside-modified viral Ag mRNA (i.m.) Zika virus NCT03014089 (I/II) Recruiting85
Influenza virus NCT03076385 (I) Ongoing22
  1. The table summarizes the clinical trials registered at ClinicalTrials.gov as of 5 May 2017. Ag, antigen; CD40L, CD40 ligand; DC, dendritic cell; EP, electroporated; i.d., intradermal; i.m., intramuscular; i.nod., intranodal; NA, not available.
PowerPoint slide